Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year trend showing gross, operating, and net profit margins
Dr Lal PathLabs's net profit margin of 19.8% in FY2025 reflects good profitability, with operating margin at 22.5% and gross margin at 66.6%.
In FY 2025, Dr Lal PathLabs posted a gross margin of 66.6%, an operating margin of 22.5%, a net margin of 19.8%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Dr Lal PathLabs's revenue grew 7.2% to 24.61B and net profit grew 34.5% to 4.87B YoY in FY2025, indicating moderate business momentum.
In FY 2025, Dr Lal PathLabs's revenue grew by 7.2% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Dr Lal PathLabs's ROE of 22.1% in FY2025 indicates excellent capital efficiency.
In FY 2025, Dr Lal PathLabs reported an ROE of 22.1%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Dr Lal PathLabs's FCF/NI ratio of 1.08x in FY2025 indicates solid earnings quality with FCF tracking net income.
In FY 2025, Dr Lal PathLabs's free cash flow exceeded net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Dr Lal PathLabs's OCF/NI ratio of 1.17x in FY2025 indicates sound cash management with earnings well-backed by cash.
In FY 2025, Dr Lal PathLabs's operating cash flow exceeded net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Dr Lal PathLabs's current ratio of 3.39x in FY2025 indicates ample liquidity, though assets may be underutilized.
In FY 2025, Dr Lal PathLabs reported a current ratio of 3.39. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Dr Lal PathLabs's interest coverage ratio of 24.8x in FY2025 indicates comfortable debt servicing capacity.
In FY 2025, Dr Lal PathLabs reported an interest coverage ratio of 24.8x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Dr Lal PathLabs's debt-to-equity ratio of 0.07x in FY2025 reflects a conservative, low-leverage capital structure.
In FY 2025, Dr Lal PathLabs reported a debt-to-equity ratio of 0.07. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Dr Lal PathLabs's debt decreased 36.2% YoY in FY2025 — positive deleveraging improves financial flexibility.
In FY 2025, Dr Lal PathLabs's total debt decreased by 36.2% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Dr Lal PathLabs's diluted shares increased 0.2% YoY in FY2025 — share dilution.
Over 2 years (FY2024–FY2025), diluted shares increased 0.2% from 166.47M to 166.84M, indicating cumulative dilution.
In FY 2025, Dr Lal PathLabs's diluted shares increased by 0.2% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025